{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:26:13Z","timestamp":1761989173525},"reference-count":39,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T00:00:00Z","timestamp":1517961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in young children. Presatovir (previously GS\u20105806) is a novel, orally administered RSV fusion inhibitor with a favorable safety profile and proven antiviral efficacy in preclinical and clinical studies. In vitro, presatovir is a substrate of the efflux transporters P\u2010glycoprotein (P\u2010gp) and breast cancer resistance protein (BCRP) and hepatic uptake transporters organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 and is slowly metabolized by cytochrome P450 (CYP) 3A4 and CYP3A5. This study enrolled 64 healthy subjects to evaluate the effect of cyclosporine, a P\u2010gp, BCRP, and OATP1B1\/1B3 inhibitor; rifampin, a strong CYP3A4 and P\u2010gp inducer; efavirenz, a moderate CYP3A4 inducer; and cobicistat, a potent CYP3A inhibitor, on presatovir pharmacokinetics. Presatovir plasma exposures (maximum observed plasma concentration [C<jats:sub>max<\/jats:sub>] and area under the plasma concentration\u2013time curve from time 0 extrapolated to infinity [AUC<jats:sub>inf<\/jats:sub>]) were not affected by coadministration of cyclosporine, suggesting presatovir is not a sensitive substrate of P\u2010gp, BCRP, or OATP1B1\/1B3. As expected, based on the role of CYP3A in presatovir metabolism, presatovir exposure was increased by cobicistat (122% in AUC<jats:sub>inf<\/jats:sub>), and decreased by rifampin (40.3% in C<jats:sub>max<\/jats:sub> and 82.5% in AUC<jats:sub>inf<\/jats:sub>) and efavirenz (55.7% in AUC<jats:sub>inf<\/jats:sub>). These data support coadministration of presatovir with inhibitors of P\u2010gp, BCRP, OATP1B1\/1B3, or CYP3A, but not with moderate or strong CYP3A4 inducers. Presatovir was well\u2010tolerated with the most common drug\u2010related adverse events of dizziness (n = 12) and somnolence (n = 4) reported during efavirenz treatment.<\/jats:p>","DOI":"10.1002\/jcph.1073","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T15:44:43Z","timestamp":1518018283000},"page":"771-780","source":"Crossref","is-referenced-by-count":7,"title":["The Drug\u2013Drug Interaction Profile of Presatovir"],"prefix":"10.1002","volume":"58","author":[{"given":"Yan","family":"Xin","sequence":"first","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnie","family":"Weng","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard P.","family":"Murray","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene J.","family":"Eisenberg","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason W.","family":"Chien","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Seattle WA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ling","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Silverman","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60206-1"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00255-6"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804877"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1067\/S0022-3476(03)00510-9"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.2.179"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23570"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2016.02.025"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043951"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw270"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis309"},{"key":"e_1_2_7_12_1","unstructured":"Centers for Diseases Control and Prevention.RSV Seasonal Trends.https:\/\/www.cdc.gov\/rsv\/research\/us-surveillance.html. Accessed April 19 2017."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12313"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S60710"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-2223"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.104.3.419"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/11531860-000000000-00000"},{"key":"e_1_2_7_18_1","volume-title":"Full Prescribing Information","author":"VIRAZOLE(Ribavirin for Inhalation Solution, USP)","year":"2016"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu828"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm5017768"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01497-15"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401184"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00487-15"},{"issue":"3","key":"e_1_2_7_24_1","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch T","year":"2007","journal-title":"Am Fam Physician"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-009-9924-0"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.20180"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03134.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00615223"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010385934"},{"key":"e_1_2_7_31_1","volume-title":"Full Prescribing Information","author":"TYBOST (cobicistat) tablets, for oral use","year":"2016"},{"key":"e_1_2_7_32_1","unstructured":"Food & Drug Administration (FDA).Guidance for Industy: Drug Interaction Studies \u2010 Study Design Data Analysis Implications for Dosing and Labeling Recommendations: Draft Guidance.2012."},{"key":"e_1_2_7_33_1","unstructured":"University of Washington.Drug Interaction Database Program.https:\/\/www.druginteractioninfo.org\/. Accessed November 15 2017."},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9290-9"},{"key":"e_1_2_7_35_1","unstructured":"JinF ChienJW MackmanR LewisS BaylyS RamanathaS.Single and multiple dose\u2010ranging evaluation of safety and pharmacokinetics of the RSV fusion inhibitor GS\u20105806. Presented at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2\u20136 2014; Washington DC."},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.276"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.228"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3028"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.570"},{"key":"e_1_2_7_40_1","volume-title":"Full Prescribing Information","author":"SUSTIVA (efavirenz) capsules and tablets for oral use","year":"2017"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.1073","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T23:20:57Z","timestamp":1694301657000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.1073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1002\/jcph.1073"],"URL":"https:\/\/doi.org\/10.1002\/jcph.1073","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,7]]}}}